Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 18, 2026.

Chitosan Modification and Pharmaceutical/Biomedical Applications

Jiali Zhang, Wenshui Xia, Ping Liu and 4 more

Marine Drugs · 2010 · Review · CC BY

doi:10.3390/md8071962

Abstract

Chitosan has received much attention as a functional biopolymer for diverse applications, especially in pharmaceutics and medicine. Our recent efforts focused on the chemical and biological modification of chitosan in order to increase its solubility in aqueous solutions and absorbability in the in vivo system, thus for a better use of chitosan. This review summarizes chitosan modification and its pharmaceutical/biomedical applications based on our achievements as well as the domestic and overseas developments: (1) enzymatic preparation of low molecular weight chitosans/chitooligosaccharides with their hypocholesterolemic and immuno-modulating effects; (2) the effects of chitin, chitosan and their derivatives on blood hemostasis; and (3) synthesis of a non-toxic ion ligand—D-Glucosaminic acid from Oxidation of D-Glucosamine for cancer and diabetes therapy.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Chitosan, a natural cationic polysaccharide, has received considerable attentions as a functional, renewable, nontoxic and biodegradable biopolymer for diverse applications, especially in pharmaceutics, food and cosmetics. In the medical field, chitosan has been developed not only as artificial skin, absorbable surgical suture, and a wound healing accelerator, but also as new physiological materials due to their antitumor, immunoenhancing, antimicrobial and hypocholesterolemic properties. These functions have been revealed to be dependent on both their chemical structure and the molecular size. As a result, the application of this native polysaccharide is limited by its high molecular weight and highly viscous nature resulting in its low solubility in acid-free aqueous media. In recent years, studies on the modification of chitosan have intensified since efficient utilization of marine biomass resources has become an environmental priority and for a better use of chitosan. This review focuses on the modification of chitosan by enzymatic hydrolysis and various chemical processes, in combination with pharmaceutical and biomedical applications especially in hypocholesterolemic, immunoenhancing, homeostasic and anticancer functions, based on our current research as well as the recent literature.

2. Structure and Characterization of Chitosan

Chitosan is a copolymer consisting of β-(1→4)-2-acetamido-D-glucose and β-(1→4)-2-amino-D-glucose units, with the latter usually exceeding 80%. The proportion of the two monosaccharide units in chitosan depends on the alkaline treatment Generally, the individual chains assume an essentially linear structure, which undergoes one full twist every 10.1–10.5 Å along the chain axis. Since each monosaccharide unit is chiral, the rotations of polymer chains show evident left or right. Accordingly, chitosan could be divided into three crystal types: α, β and γ type, which could be identified by X-ray model and NMR spectra. Among these, α-type is the most common type obtained from crust of shrimp and crab.

Chitosan has three types of reactive functional groups, an amino/acetamido group as well as both primary and secondary hydroxyl groups at the C-2, C-3 and C-6 positions, respectively. The amino contents are the main factors contributing to differences in their structures and physico-chemical properties, and its distribution is random, which make it easy to generate intra- and inter-molecular hydrogen bonds.

Many novel chitosan derivatives have been obtained by chemical modification using the reactive activities of hydroxy- and amino groups. In particular, the amino group has nucleophilic property, allowing easy formation of imine by reaction with aldehyde or corresponding amide derivatives in acylating reagents; in acidic solution, the amino groups showe alkaline properties and receive protons to generate salts, presenting cationic polymer properties. Besides, the amino functional group has also been correlated with chelation, flocculation and biological functions. The characterization of a chitosan sample requires the determination of its average Degree of acetylation (DA). The distribution of acetyl groups along the chain (random or blockwise) may influence the solubility of the polymer and also the inter-chain interactions due to H-bonds and the hydrophobic character of the acetyl group. This distribution has been evaluated by various techniques such as IR, elemental analysis, enzymatic reaction, UV, 1H liquid-state NMR and solid-state 13C NMR. Diad and triad frequencies were determined for homogeneous and heterogeneous chitosan with different values of DA.

Another important characteristic to consider for these polymers is the molecular weight and its distribution. The first difficulty encountered in this respect concerns the solubility of the samples and dissociation of aggregates often present in polysaccharide solutions. As to choice of a solvent for chitosan characterization, various systems have been proposed, including an acid at a given concentration for protonation together with a salt to screen the electrostatic interaction. The solvent is important also when molecular weight has to be calculated from intrinsic viscosity using the Mark-Houwink relation. High molecular weight chitosan is estimated to be 106. High molecular weight chitosans (HMWC) form solutions with higher viscosities than chitosans of lower molecular weight. Polymeric chitosan is soluble in acidic conditions and is insoluble at pH values above 6.3 (the pKa of chitosan). However, chitosan oligomer has a low viscosity, and is freely soluble at neutral pH. Production of low molecular weight chitosan (LMWC) and chitooligosaccharides (COS) from the hydrolysis of chitosan can be achieved either by chemical or enzymatic methods. The chemical method needs high energy and is hard to control; hence, the enzymatic hydrolysis of chitosan offers many advantages. During preparation of different molecular weight chitosans, viscosity is used as a parameter to determine the molecular weight.

Unlike most polysaccharides, chitosan, LMWC and COS have positive charges, which allows them to bind strongly to negatively charged surfaces; this property is responsible for many of the observed biological activities. However, it is important to mention that chitosans with different structures show different biological activities, and not all biological activities are found in one kind of chitosan. Each special type of bioactive chitosan has been developed by chemical modification and enzymatic hydrolysis for its potential pharmaceutical and medical application.

3. Enzymatic Preparation of LMWC and COS and Their Hypocholesterolemic and Immunoenhancing Effects

In general, for preparation of COS and LMWC, chitosan can be hydrolyzed enzymatically by specific chitosanases and non-specific enzymes. The specific enzyme for chitosan hydrolysis has been found in a wide range of organisms, including bacteria, fungi and plants. Most of these chitosanases are characterized as endo-type and they split β-1,4 glycosidic linkages in chitosan in a random way to form chitosan oligomers. However, the utility of these specific chitosanases in hydrolysis is limited because of its cost and unavailability in large quantities. Nowadays, on the one hand, kinds of physical/chemical induction and molecular evolution of special chitosanases have been attempted to obtain higher activity and stability. On the other hand, many researchers have been devoting themselves to exploring novel sources of chitosanases. Whereby, a number of non-specific commercial enzymes have been found for their ability to degrade chitosan with efficiency comparable to that achieved by chitosanases. Based on long-term work, we have made some achievements in both molecular evolution of special chitosanases from fungi and the chitosan-hydrolysis of these nonspecific enzymes as well as preparation of many kinds of LMWCs and COSs.

3.1.1. Non-specific enzymatic preparations of LMWCs

The reactions of non-specific chitosanolysis are of great interest as these commercial enzymes have been used in the food industry for decades. They were found to be safe and relatively low-cost. Another advantage is the ease of production of LMWCs in higher yields due to their low specificity or nonspecificity. However, the nonspecific hydrolysis mechanisms are still disputed. Here we review the characterization and mechanism of chitosan hydrolysis based on the action of three typical non-specific enzymes: cellulase, lipase and papain.

3.1.1.1. Cellulase-treated chitosan

Cellulase was one of the two nonspecific enzymes firstly reported with chitosanolysis properties and it also exerted comparable chitosanolytic activity with the specific chitosanases. There are various reports on chitosan hydrolysis by cellulases. We also studied the characteristics and mechanism of cellulase treating chitosan. We were led to conclude that not a single chitosanolytic component existed in fungal commercial cellulases prepared from Trichodrma viride, exerting both exo- and endo-split pattern. The commercial cellulase could catalyze the hydrolysis of chitosan substrates with a wide range of acetyl groups and showed similar effects on chitosans with DA less than 30%. The optimal temperature for cellulase to function on chitosan was between 50 ºC and 60 ºC and the optimal pH was in the range of 5.0 to 7.0. The products of standard COS and chitosan digestion were analyzed by thin layer chromatography (TLC), Liquid chromatography mass spectrometry (HPLC/MS) and time course analysis. Results demonstrated that it could cleave GlcN-GlcNAc, GlcNAc-GlcN as well as GlcN-GlcN bonds from the non-reducing end of the chitosan chain. Chitosan was extensively depolymerized into a range of molecular weights (Mw) from 286 kDa to 1588 kDa and deacetylated from 82% to 94%. Eight partial depolymerized chitosans were prepared. About the mechanism, one bifunctional enzyme with chitosanolytic and cellulolytic activity (CCBE) from cellulase (T. viride) has been purified and further identified as a cellobiohydrolase I with exo-β-D-glucosaminidase activity, belonging to glycosyl hydrolysase seven families.

3.1.1.2. Lipase-treated chitosan

Chitosan hydrolysis by lipase was firstly studied by Muzzarelli et al.. In 2001, the degradation of chitosan was further studied with the aid of lipase from Rhizopus japonicus for the production of soluble chitosan, showing that lipase could degrade chitosan to water-soluble LMWC with Mw between 30–50 kDa at the optimal temperature of 40 ºC. In a recent study, we investigated the effects of a commercial lipase from A. oryzae on chitosan hydrolysis systematically with different parameters such as pH, temperature, DA, Mw, viscosity reduction, and qualitatively analyzed COS products using kinetic analysis, TLC and HPLC methods. When four chitosans with various DA were used as substrates, the lipase exhibited higher optimal pH toward chitosan with lower DA. The optimal temperature of the lipase was 55 ºC for all chitosans. The enzyme exhibited higher activity to chitosans deacetylated at the level of 82.8% and 73.2%. Kinetics experiments showed that these two kinds of chitosan also had stronger affinity for the lipase. The chitosan hydrolysis carried out at 37 ºC produced larger quantity of COS than that at 55 ºC when the reaction time exceeded 6 h, and COS yield of 24 h hydrolysis at 37 ºC was 93.8%. Product analysis results demonstrated that the enzyme produced glucosamine and COSs with polymerization degree (DP) of 2–6 and above, and acted on chitosan in both an exo- and endo-hydrolytic manner. Moreover, one main chitosanolytic component with chitinase activity (CNBE) was purified from this commercial lipase (A. oryzae), and was identified as the exo-β-D-glucosaminidase with N-acetyl-chitobiosidase activity, belonging to glycosyl hydrolysase 18 family.

3.1.1.3. Papain-treated chitosan

It has been reported that papain degrades chitosan under optimal the pH condition of 3.0–4.0 and temperature of 40–50 °C, although different papains were used in different researches. Chitosan with Mw of 4–5 × 105 was degraded by papain to produce the LMWC and COS in a range of 103–105. Chitosan depolymerization was reported by papain in the form of its lactate salt at acidic pH values. Chitosans with average molecular weights in the range of 4–7 × 105 could be easily depolymerized to highly polydisperse chitosans. Modified chitosans were also depolymerized, though with lower initial velocities. The molecular parameters of chitosan depolymerized with the aid of papain were also studied, revealing that preference was for chitosan with highest DP. The papain mainly cleaved the GlcN-GlcNAc bond in chitosan. However, our previous research found that papain could split the GlcNAc-GlcN as well as GlcN-GlcN bond and produced the mixture of LMWC and COS with DP of 2–6 after 24 h hydrolysis. The optimal degradation conditions were at pH 4.0 and 40 ºC, taking 14.3% DA chitosan (0.5% concentration) as the substrate. Papain initially degraded quite quickly in the reaction, the rate of decline in viscosity was evaluated at 70.77% in 30 min then stabilized after 1 h. LMWCs with 4.1–56 kDa could be obtained. Moreover, we discovered that papain has at least three hetero chitosanases responsible for its chitosanolytic activity.

3.1.2. The hypocholesterolemic effects of different prepared LMWCs

Growing evidence indicates that chitosan can lower plasma and liver triacylglycerol (TG) as well as total cholesterol (TC) levels, exhibiting hypocholesterolemic and hypolipidemic effects. It has been reported that chitosan can reduce the risk of cardiovascular diseases and has potent fat-binding capacity in vitro. In addition, chitosan was also shown to increase fecal-neutral-steroid and bile-acid excretion in rats and lower the postprandial plasma TG level in broiler chickens. Among these, the hypocholesterolemic effect of chitosan was reported in humans for the first time by Maezaki et al., they found that chitosan effectively decreased plasma lipid levels without side effects. However, controversy still exists surrounding the mechanism of the hypocholesterolemic and hypolipidemic effects of different chitosans. Taking into consideration that the DA and Mw of chitosan are two important characteristics that greatly affect its chemical and physiological properties, in combination with the state of chitosan, our recent work studied the effects of DA, Mw and particle size of different solid LMWCs prepared by commercial cellulase on hypocholesterolemia in vitro and in vivo.

The results of fat-, cholesterol- and bile-salts-binding capacities of different LMWC samples in vitro indicated that the fat-binding capacity of LMWCs was significantly higher than that of cellulose, and it increased with increasing DA and Mw, while the cholesterol-binding capacity did not show significant variation with changes of DA and Mw, but was affected by the particle size. However, the bile-salt-binding capacity was greatly affected by Mw: the sample with the highest Mw showed the best binding capacity for bile salts, while the DA and particle size seemed to have no evident effect on the bile-salt-binding capacity. These results verified that the physicochemical properties of LMWCs affect its binding capacities and hypocholesterolemic and hypolipidemic activities in vitro.

The hypocholesterolemic effects of LMWCs with different physiochemical properties were further investigated in vivo. Rats fed diets containing the lowest-DA chitosan showed significantly lowered plasma triglyceride, total cholesterol and low-density-lipoprotein cholesterol (LDL-C) levels as well as elevated high-density-lipoprotein cholesterol (HDL-C) levels, although not all differences were significant. Moreover, the food-efficiency ratio also decreased with decreasing DA. This is in conformity with the results observed by Deuchi et al.. LMWCs with higher Mw limited the body-weight gain of adult rats significantly, reduced the food-efficiency ratio and lowered plasma lipids. These results confirmed the effect of viscosity on hypocholesterolemic activity but also indicated that the viscosity was not the major factor influencing the hypocholesterolemic effects of chitosan in the upper gastrointestinal tract. Above a certain viscosity, the effect was small with increasing Mw. The particle size of LMWCs also evidently affected its hypocholesterolemic effect. LMWCs with a fine particle size effectively lowered plasma and liver lipid levels in rats. In addition, the powdered form of LMWCs exhibited a greater rate of adsorption of oil than the flake type. We also found that the particle size of LMWCs was the main property affecting its hypocholesterolemic effect. This is consistent with the report that powdered chitosans exhibited better cholesterol- binding capacity than cellulose, while chitosan in the flake form bound less cholesterol than cellulose.

Therefore, we can conclude that the physicochemical properties of LMWCs affect their hypocholesterolemic activities. The effects are more pronounced when the particles are finer in combination with lower DA and higher Mw.

3.1.3. The hypocholesterolemic mechanism of LMWCs via adsorption, electrostatic force and entrapment

The hypocholesterolemic activity of LMWCs was higher when its DA was lower (90% deacetylated) at equal Mw and particle size; this might be due to the electrostatic attraction between LMWCs and anionic substances such as fatty acids and bile acids. In addition, when fat and LMWCs are eaten together, the viscous LMWCs will entrap the fat droplets in the stomach. When the complex arrives at the small intestine, LMWCs precipitate together with the entrapped fat at neutral pH to prevent the digestion of fat; this has been proven in vitro. When the DA and the particle size are comparable, the fat-binding capacity of LMWCs is enhanced with increasing Mw, suggesting that during the fat-binding process, the fat molecules are embedded in the long chain of chitosan; hence, a larger molecular weight means a longer chain and thus more fats will be embedded. Therefore, the electrostatic interactions with and entrapment of fat by the viscous polysaccharide chitosan, which would reduce the absorption of fat in the diet, was regarded as one factor in the fat-binding mechanism. This factor also resulted in a better fat-binding capacity of chitosan than for cellulose. Moreover, at the same Mw, powdered chitosan has a smaller particle size, a higher total surface area and a more open pore structure than flake chitosan, facilitating adsorption. This suggests that the interaction between chitosan and bile salts as well as cholesterol is adsorption, which also contributes to its hypocholesterolemic effect. However, this adsorption function is likely weakened in vivo as chitosan can be dissolved in the acidic conditions of the stomach.

From the above, it is a conclusion that the combined effects of electrostatic attraction, embedding, adsorption and entrapment were the probable mechanisms of the hypocholesterolemic effects of LMWCs, which was further confirmed by the results of distribution and metabolism of LMWCs in rats through measuring the content of fluorescein isothiocyanate labeled chitosan (FITC-CIS) in vivo. Therefore, hypocholesterolemic mechanisms of LMWCs were identified as the combination of adsorption, electrostatic force and entrapment.

3.2.1. Enzymatic Preparations of COSs by fungi specific chitosanases

The higher yield and activity of special chitosanases is a long-term pursued project. Until now, the highest activity chitosanases and the commercial chitosanase preparation are all produced from bacteria such as Streptomycete, most from which belong to the glycosyl hydrolysase 46 family. However, yields were low, resulting in high costs and limitations in application. Fungi are potentially an excellent source of chitosanases since they secrete chitosanase extracellularly, avoiding cytotoxicity and product inhibition.

Aspergillus has been reported broadly and is regarded as a powerful candidate for special chitosanase production. In our previous study, Aspergillus CJ22-326—a fungi strain capable of utilizing chitosan as a carbon source—was isolated from soil samples. Two types of chitosanase (ChiA and ChiB) produced from the culture supernatant of Aspergillus CJ22-326 were purified to an apparent homogeneity, identified by SDS-PAGE through ammonium sulfate precipitation, CM-Sepharose FF chromatography, and Sephacryl S-200 gel filtration. Molecular weights of the enzymes were 109 kDa (ChiA) and 29 kDa (ChiB). Optimum pH values and temperature of ChiA were 4.0 and 50 °C, respectively, those of ChiB were 6.0 and 65 °C. Viscosimetric assay and analysis of reaction products of these enzymes, using chitosan as a substrate, by TLC indicated endo- and exo-type cleavage of chitosan by ChiB and ChiA, respectively. ChiA released a single glucosamine residue from chitosan and glucosamine oligomers. ChiB catalyzed the hydrolysis of glucosamine (GlcN) oligomers larger than a pentamer, and chitosan with a low DA (0–30%), and formed chitotriose with chitohexaose as the major products. Both of the activities of ChiA and ChiB increased proportionally with the DA decreasing of chitosan. In addition, many chemical and physical methods have been used to improve the CHiB activity.

Furthermore, in order to improve the chitosanolytic activity, recently, both ChiA and ChiB genes were cloned, site-directly mutated and expressed in E. coli. The recombinant ChiB exhibited higher chitosanolytic activity than previously reported fungal chitosanases. The enzyme ChiB had a useful reactivity and a high specific activity for producing functional COS with high DP. Base on the amino acid similarity, ChiB exhibited high homology to other fungal chitosanases from Fusarium solani, which belonged to glycosyl hydrolysase 75 family.

In addition, we also utilized the chitosanase from A. fumigatus BSF114 to produce COSs with the DP of 3–7. Chitosan pentamer ((GLcN)5) and chitosan hexamer ((GLcN)6) were isolated and purified from COS by the ultra-filtration, nano-filtration, ethanol precipitation and the CM-Sephadex C-25 column. (GLcN)5 consisted of (GlcN)4 (59.84%) and (GLcN)5 (40.16%). (GLcN)6, however, mainly consisted of (GLcN)6 (93.11%) and (GLcN)5 (6.89%). These COSs were used for immunomodulating research.

3.2.2. The immuno-modulating effect and mechanism of COSs

Previous studies showed that COS possesses not only some similar properties with chitin and chitosan, but also special physiological or functional properties that differ from chitin and chitosan. Immune activities of COS have attracted interest among researchers. A LMWC and a COS mixture isolated from this chitosan hydrolysate have different stimulatory effects on the cell proliferation and IgM secretion of the human hybridoma HB4C5 cells. Oligochitosan consisting of chitohexaose has been reported to have a stimulatory effect on the release of interleukin 1β (IL-1β) and necrosis factor-alpha (TNF-α) in macrophages in vitro. A quantity of investigations indicated that the immunoregulatory function of polysaccharide is due to the combination of polysaccharide and the lymphocyte surface receptor, namely complement III receptor (CR3). However, effect of the DP of COS on gene expression and secretion of cytokines was not understood. Herein, the immune mechanism of higher DP chitooligomers ((GLcN)5 and (GLcN)6) obtained by enzymatic hydrolysis of chitosan on gene expression was studied.

CR3 was initially described as an opsonic receptor. Subsequently, CR3-mediated lectin-sugar recognition mechanisms have been shown to play a major role in the phagocytosis of several pathogens. Effects of (GLcN)5 and (GLcN)6 in vivo and in vitro on gene expression of cell surface CR3 receptor were investigated by relatively quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Enzyme-linked immunosorbent assay (ELISA). The results showed that the expression of CR3 mRNA could be promoted by both (GLcN)5 and (GLcN)6. The promotion effect caused by (GLcN)6 was greater than that of (GLcN)5. The possible mechanism was that the polysaccharide bound the binding site of CR3 and changed the configuration of the receptor. The change of configuration can adjust the toxicity of target cells conditioned by iC3b. After binding to the CR3 receptor, (GLcN)5 and (GLcN)6 can activate phagocytes to improve the phagocytic ability and enhance the antibody transmission ability. Moreover, it can activate T cells and B cells and enhance their conjugated effect in the immune response. The molecular weight of (GLcN)6 is higher than that of (GLcN)5, and relatively, the amount of amino groups exposed of (GLcN)6 is also larger than that of (GLcN)5. Therefore, (GLcN)6 has more active binding sites to combine with the CR3 receptor surface of macrophage and lymphocyte. And also (GLcN)6 can change the configuration of CR3 receptor to show higher affinity for CR3 receptor.

Moreover, the effect of COSs on gene expression of important cytokines such as IL-1 and TNF-α in Mf as well as IL-2 and interferon-γ (IFN-γ) in lymphocytes were also studied using cell proliferation assay in our team. Our results indicated that (GLcN)6 and (GLcN)5 could promote the immune mediation of mice in relation with the gene transcription level of IL-1, TNF-α and IFN-γ as well as the protein translation level of these cytokines. The promotion effects caused by (GLcN)6 were greater than that of (GLcN)5. This result was in accordance with previous reports. After mice were treated with chitin oligosaccharides or chitosan oligosaccharides, Mf were activated and adjusted mutually with other components of the immune system which hastened the production of reactive medium such as reactive oxygen and NO. COSs could either directly kill pathogen micro-organisms or tumor cells by exerting an immune response, or enhance cytotoxic activity and then inhibit tumor cell production by activating T-cells, NK-cells and some other immune cells through some cytokines such as IL-1 and TNF-α. TNF-α could exert synergetic effects and adjust the proliferation of Th1 cell systems together with IL-1 and IL-2 in vitro. These results indicate that COS induced innate immune responses by up-regulating IL-1, TNF-α and IFN-γ and then played a role in immune functions of lymphocytes. This may be one of the molecular mechanisms for elucidating the immunity of COS.

4.1. Quality Requirements for Chitosan as a Hemostasis Material

Research showed that whole blood formed a coagulum rapidly upon exposure to chitosan. The following studies have shown that chitosan acts as a hemostatic agent and may be used in various wound healing applications such as hemostatic bandages. However, chitosan, only in its purest form, has an internal hemostatic dressing potentiality, as a drug delivery agent, tissue scaffolding and numerous other health related products. As a natural product derived from the shells and components of organisms found in natural environments, chitosan carries a variety of contaminants, common to biologically derived materials such as protein and endotoxin, which varies from batch to batch, and thus must be carefully purified; subsequently, the resultant stimulatory immune responses in humans and animals is to be understood prior to medically related applications. Recently, various chitosan-containing medical devices such as the hemostatic Celox for the treatment of bleeding, and bandages such as HemCon or QuikClot for the control of bleeding, are marketed in Europe and US. These companies utilize processes that eliminate contaminants such as proteins, bacterial endotoxins and toxic metals, practicing Good Manufacturing Practice (GMP) guidelines. Besides, there are many reports on the preparation of high purity chitosan for medical grade through getting rid of the protein, lipid, metals and endotoxin and chitins contaminated by metals are unsuitable for the preparation of medical grade chitosan.

4.2.1. The hemostatic effect of chitin and chitosan

Since Muzzarelli described the properties of chitin in human wounds in 1977, a lot of research has been initiated all over the world into the hemostatic activities of chitin and chitosan. The effects of chitin and chitosan suspensions (0.0001–1.0 mg/mL) on blood coagulation were evaluated by Okamoto et al., the results of the blood coagulation time (BCT) showed that chitin and chitosan reduced BCT significantly in a dose-dependent manner, and they enhanced the release of the platelet derived growth factor-AB (PDGF-AB) and the transforming growth factor-β1 (TGF-β1) from the platelets, particularly with chitosan. Even in a therapeutically anticoagulated (heparinized) rabbit model, chitosan treatment could effectively bring bleeding time within the normal range. The same conclusion was reached when Wang et al. compared the hemostatic ability of chitosan and collagen sponge. For both chitosan and collagen sponges, the total amount of bleeding from the injured veins until hemostasis and the complete hemostasis success rates were similar. But the chitosan sponges strongly adhered to the surface of the rabbit muscles, whereas the collagen sponges were easily detached from the muscles. A fly-larva shell-derived chitosan sponge (CS) was evaluated as an absorbable surgical hemostatic agent in a rat hepatic hemorrhage model, indicating that CS was a suitable implantable hemostatic material when compared to gelatin sponge or oxidized cellulose in both acute and chronic bleeding models. Recently developed internal chitosan bandages have been effective in achieving rapid hemostasis in large surgical and traumatic lacerations of the aorta, liver, lung, kidney and cardiac ventricles. However, there is little research on the blood coagulation of chitosans with different physicochemical properties. Our recent study measured the in vitro coagulative activity of chitosan hydrochloride solution with different DA and Mw using tube and capillary tube methods. The results indicated that the DA and Mw of chitosan had great influence on the hemostasis of chitosan hydrochloride solution: this chitosan with higher DA and Mw exhibited better hemostatic activity, while the effect of DA and Mw was slight on the powder chitosan. From this, it can be deduced that the hemostatic mechanisms of chitosan in powder and hydrochloride solution were different. Meanwhile, organ damage in vivo experiments in rabbits showed that chitosan could promote rapid blood clotting at a wound injury in lung, spleen and kidney, and also reduce the amount of bleeding, exerting a good in vivo hemostatic effect.

4.2.2. The hemostatic effect of chitosan derivatives

Based on the excellent hemostatic activity, lots of chitin and chitosan derivatives with different chemical or spatial structures have been explored. N,O-carboxymethylchitosan (NOCC) could decrease the whole blood clotting time (WHBCT) and lower the plasma recalcification time (PRT) value, similar to that of chitosan and chitin. When used in a hypothermic coagulopathic grade V liver injury, Bochicchio et al found that a modified chitosan patch (MCP) could significantly reduce the post treatment blood loss and increase resuscitation mean arterial pressure (P < 0.0001 and P < 0.018, respectively). The photocrosslinkable chitosan (Az-CH-LA) is a chitosan hydrogel containing both lactose moieties and photoreactive azide groups. The sealing ability of this chitosan hydrogel expressed stronger similarity to that of fibrin. The photocrosslinkable chitosan has been used for endoscopic cancer treatment in the alimentary tract. It could completely stop the bleeding from a cut mouse tail within 30 s of UV-irradiation and could firmly adhere two pieces of sliced mouse skin to each other. Its hemostatic effect is independent of the blood coagulation. Moreover, a series of new in situ-forming hydrogels, composed of oxidized dextran (Odex) and amine-containing polymers including polyallylamine (PAA), oligochitosan and glycol chitosan, have been developed. Some scholars also explored chitosan derivatives with the amino group introduction by using Ar, O2, NH3 and NH3-He mixed gas plasmas. These samples all showed shorter blood clotting time, while the best was with treatment by NH3 and He plasma with O2 pretreatment.

Among these, chitosan-Glycerol Phosphate hydrogels were the most attractive, and have been deeply developed. Chitosan-glycerol phosphate (chitosan-GP) is a unique polymer solution that is mixed with whole blood and solidified over microfractured or drilled articular cartilage defects in order to elicit a more hyaline repair cartilage. It was found by Buschmann that chitosan-GP/blood clots showed increased adhesion to the walls of the defects as compared with the blood clots in the untreated microfracture defects. After histological processing, all blood clots in the control microfracture defects had been lost, whereas chitosan-GP/blood clots adhered to and were partly retained on the surfaces of the defect. At six months, defects that had been treated with chitosan-GP/blood were filled with significantly more hyaline repair tissue (p < 0.05) compared with control defects. Repair tissue from medial femoral condyle defects that had been treated with chitosan-GP/blood contained more cells and more collagen compared with control defects and showed complete restoration of glycosaminoglycan levels. These results indicated that solidification of a chitosan-GP/blood implant in microfracture defects improved cartilage repair compared with microfracture alone by increasing the amount of tissue and improving its biochemical composition and cellular organization. Later, they further studied the effects of the chitosan-GP/blood implant and of debridement on the formation of incipient cartilage repair tissue by histology and in vitro clot retraction tests. They found that chitosan-GP solutions structurally stabilized the blood clots by inhibiting clot retraction. Chitosan-GP/blood implants applied in conjunction with drilling, compared to drilling alone, elicited a more hyaline and integrated repair tissue associated with a porous subchondral bone replete with blood vessels. Concomitant regeneration of a vascularized bone plate during cartilage repair could provide progenitors, anabolic factors and nutrients that aid in the formation of hyaline cartilage. In addition, a series of chitosan-polyphosphate dressings were fabricated and the optimal chitosan-polyphosphate formulation (coded as ChiPP) accelerated blood clotting (p = 0.011), increased platelet adhesion (p = 0.002), generated thrombin faster (p = 0.002), and absorbed more blood than chitosan (p < 0.001).

Based on the hemostatic properties reported from studies of chitin, chitosan and their derivatives, commercial chitin- and chitosan-based hemostatic dressings have flooded the market (see Table 1) and are used in medicine.

4.3. The Hemostatic Mechanism of Chitosan and Its Derivatives

Due to the effects of chitosan and its derivatives on hemostasis, there are lots of reports on studies of the mechanism in vitro and in vivo. Although there is still no assured verdict of the mechanism by which they function to stop bleeding, several factors are thought to contribute to the hemostatic function.

4.3.1. The hemostatic mechanism of chitosan

Studies indicate that chitosan’s hemostatic mechanism seems to be independent of the classical coagulation cascade. It has been found that coagulation factors could not be activated by chitosan and its derivatives, and no activation of the intrinsic pathway was observed by Benesch et al.. Chitosan’s putative capacity to induce clot formation in the absence of coagulation factors could prove to be useful for patients with coagulopathies or those who are therapeutically anticoagulated, since chitosan keeps ability to maintain hemostasis in the presence of heparinized blood. Most of all, numerous articles reported the interactions between chitin/chitosan and platelets. These studies suggested that chitin and chitosan directly influenced platelets by themselves and this effect was enhanced in the presence of plasma. Some researchers regarded that chitosan likely function independently of platelets because it could induce clot formation in the absence of platelets, however, over time, more and more researchers admit that the hemostatic effects of chitosan are related to both platelets and erythrocyte aggregations. The blood clot formed in the chitosan-treated lingual incisions was evaluated by scanning electron microscopy, and it showed an interesting phenomenon: when the blood mixed with chitosan acetic-acid physiological saline solution, the erythrocytes aggregated and were deformed. The deactylation degree in the chitosan acetic acid physiological saline solution - especially a low deactylation degree - had a significant effect on the unusual aggregation and deformation of erythrocytes, compared with the effect of Mw within a range between 105 and 106. However, this phenomenon could not be observed in solid-state chitosan soliquoid. Our recent research also demonstrated that the hemostasis of chitosan has no direct relation to the traditional intrinsic or extrinsic pathways, but it could promote the adhesion and aggregation of platelets. Platelets play a very important role in coagulation and could promote hemostasis and thrombosis. The membrane space configuration changes and the platelet-derived microparticles (PMPs) are released in the activated platelets, then the exposed platelet glycoprotein IIb-IIIa receptor complex interacts with fibrinogen, resulting in platelet accumulation, and ultimately initiating the chain reaction of coagulation. Binding or agglutination of red blood cells in the presence of chitosan is dependent on its physical characters, particularly on molecular size. The ionic attraction between negatively charged red blood cell membranes and positively charged groups in chitosan is a possible explanation for the anticoagulant activity of chitosan. Therefore, positively charged chitosan is more effective than chitin as a blood coagulant.

Except for platelets and erythrocytes, chitosan also accelerated thrombin generation in a statistically significant manner compared to the saline control, with a trend towards chitin being more thrombogenic. Upon acetylation, the chitosan layer became a strong activator of the alternative pathway of the complement system.

4.3.2. The hemostatic mechanism of chitosan derivatives

Except for the hemostatic mechanism of chitosan itself, the hemostatic responses to its derivatives highly depend on their chemical nature such as the added functional groups. Hence, different chitosan derivatives are involved in different hemostatic mechanisms. For example, carboxymethyl chitosan physiological saline solution had nothing to do with the aggregation and deformation of erythrocytes but caused local rouleau. The morphology of red blood cells binding surface on chitin and chitosan was examined, with approximately 10-fold lower levels and with less distinct general morphologies than the highly structured β-pGlcNAc.

Chitosan-glycerol phosphate (chitosan-GP) is one of the most popular chitosan derivatives and underwent detailed research by the company Buschmann and Biosyntech through investigating the hemostatic mechanisms underlying chitosan-GP/blood implant solidification in vitro and in vivo. They found that chitosan-GP/blood clots solidified in an atypical biphasic manner, with higher initial viscosity and minor platelet activation followed by the development of clot tensile strength concomitant with thrombin generation, burst platelet and FXIII activation. Whole blood and chitosan-GP/blood clots developed a similar final clot tensile strength, while polymer-blood clots showed a unique, sustained platelet factor release and greater resistance to lysis by tissue plasminogen activator. Thrombin, tissue factor (TF), and recombinant human activated factor VII (rhFVIIa) accelerated chitosan-GP/blood solidification in vitro (P < 0.05). Pre-application of thrombin or rhFVIIa + TF to the surface of drilled cartilage defects accelerated implant solidification in vivo (P < 0.05). In conclusion, chitosan-GP/blood implants solidify through coagulation mechanisms involving thrombin generation, platelet activation and fibrin polymerization, leading to a dual fibrin-polysaccharide clot scaffold that resists lysis and is physically more stable than normal blood clots. Clotting factors have the potential to enhance the practical use, the residency, and therapeutic activity of polymer-blood implants.

5. Synthesis of D-Glucosaminic Acid by Oxidation from D-Glucosamine: A Useful Metal Chelate for Anticancer and Anti-Diabetic Purposes

D-glucosamine is a structural unit of chitosan, and is produced commercially by the hydrolysis of chitosan in hydrochloric acid. D-glucosamine could be oxidized to D-glucosaminic acid. D-glucosaminic acid is one of the carbohydrate units used to manufacture various biotic substances. It has various physiological functions.

5.1. Biological Activities of D-Glusosaminic Acid

In recent years, research on D-glucosaminic acid has increased because of its industrial, agricultural, food and medical applications. D-glucosaminic acid has recently been identified as a promising sweetener and condiment. It is also a member of the “chiral pool” and has been used as a starting material for the asymmetric synthesis of various amino acids and several glycosidase inhibitors. In addition, D-glucosaminic acid has recently been investigated as an unusual component of Rhizobium leguminosarum lipopolysaccharide, and its use as a cation coordinating agent has been widely studied. Among these, the most remarkable was investigation of D-glucosaminic acid as a biocompatible, non-toxic ligand chelated with many metals for potential medical applications.

D-glucosaminic acid iron (III) complexes are potential pharmaceuticals in human and veterinary iron therapy since their stabilities are high enough to prevent metal ion hydrolysis in biological systems. Water-dispersed magnetic nanoparticles were successfully developed through glucosaminic acid-surface modification of iron oxide nanoparticles and its anticancer effect was then studied by Yu et al.. The resultant glucosaminic acid-modified magnetic nanoparticles (GA-MNPs) had not only good uniformity in spherical shape with diameter of about 10–13 nm, but also possessed excellent water-dispersal and stability. In cell culture experiments, the internalization of GA-MNPs into different kinds of cells was observed over a five-day period. The results indicated that the internalization of GA-MNPs into mouse macrophage cells and mouse embryonic fibroblast cells was not observed after 40 h of culturing. However, the GA-MNPs were internalized quickly into cancer cells after just 24 h of culturing. TEM images of the GA-MNPs uptake in ECA-109 cells were used to study the internalization mechanisms of GA-MNPs and their distribution in ECA-109 cells. Besides this, the platinum(IV)/D-glucosaminic acid complex has received considerable attention for cancer therapy because of lower toxicity and the possibility of oral administration.

Moreover, D-glucosaminic acid has also been selected to design a new kind of chromium drug candidate for anti-diabetic purposes. Two chromium (III) 1:1 and 2:3 (Cr: glucosaminate) complexes of glucosaminic acid were synthesized by neutralization and exchange reaction. The effect of the complexes on decreasing blood sugar was investigated on type-2 diabetes model rats induced by tetraoxypyrimidine. The results indicated that the effect on decreasing blood sugar was comparable to that of picolinate chromium complex (Cr (pic)3) currently used worldwide.

5.2. Synthesis of D-Glucosaminic Acid by Oxidation from D-Glucosamine

The molecular structure of D-glucosaminic acid is shown in Figure 1. Three synthesis strategies have been reported for D-glucosaminic acid from D-glucosamine: metallic catalytical oxidation, electrocatalytical oxidation and biosynthesis methods. A summary of the methods is given in the following context.

5.2.1.1. Oxidations with HgO and Hg(Ac)2

The classical synthesis of D-glucosaminic acid from D-glucosamine involves the use of yellow mercuric oxide as an oxidant, or mercuric acetate, followed by treatment with hydrogen sulfide, in a totally non-ecological process. One century ago, the yields of these procedures were not consistent (about 54%) and the resulting mercuric sulfide was difficult to separate from the products, which limited applications of D-glucosaminic acid in the food and pharmaceutical industries. However, recently we chose one novel separation method, the process was effective in a short time and the purity was higher than 95%. The yield of production through this process was estimated at a minimum of 50% of the amount of D-glucosamine chloride in use.

5.2.1.2. Platinum and Palladium Catalyzed Oxidations

The oxidation of mannose over a platinum black catalyst was the first application in the field of carbohydrates. Subsequently, the catalytic oxidation of carbohydrates over platinum on carbon was extensively studied. Like platinum, the related noble metals palladium and rhodium are known to catalyze alcohol oxidations with O2. The oxidation of carbohydrates catalyzed by platinum and palladium has been reviewed a number of times. D-glucosamine can also be oxidized by O2 with platinum and palladium catalysts, as can be seen in Table 2.

Based on our recent research and the literature, we concluded that the noble metal catalyzed oxidation of D-glucosamine to D-glucosaminic acid is essentially an oxidative dehydrogenation reaction, like alcohols and aldehydes (see Figure 2). The substrate is dehydrogenated by the noble metal, followed by oxidation of the adsorbed hydrogen atoms. Poisoning of the catalyst by molecular oxygen occurs by formation of sub-surface platinum or palladium oxide resulting from oxygen adsorption of the surface in the absence of a reducing agent. This poisoning can be limited using a low oxygen pressure but cannot be precluded entirely. However, the catalyst can be regenerated using hydrogen as the reducing agent to regain the original activity. Otherwise, this poisoning can be precluded entirely by using both Pd and Pt catalysts doped with bismuth, where bismuth acts as an assistant catalyst, avoiding the overoxidation of the palladium and platinum surface. For this reason, the yield of D-glucosaminic acid with active charcoal supported Pd-Bi catalyst is much higher than with the other catalysts. Moreover, the preparation of D-glucosaminic acid by use of molecular oxygen as an oxidant and Pd-Bi/C as a catalyst presents some additional advantages, namely, (i) high selectivity and mild reaction conditions (oxidation with molecular oxygen at atmospheric pressure near room temperature); (ii) the possibility of conducting the oxidation in one step in a single reaction vessel; (iii) a higher site-time yield per catalyst mass; (iv) a much shorter reaction time (3 h). Moreover, the catalytic process is environmentally clean since it is conducted on recyclable catalysts and gives no noxious effluents or side products. Therefore, this method is more attractive for the oxidation of D-glucosamine. The method further aims to ensure easy removal of the catalyst from the reaction mixture and to enhance its mechanical stability, as well as to enable operation in a fixed or suspended bed.

5.2.2. Biosynthesis methods

Two main strategies including enzymatic and microbiological methods are used to synthesize D-glucosaminic acid from D-glucosamine. A combination system of glucose oxidase (EC 1.1.3.4) and Catalase (EC 1.11.1.6) has high catalytic activity (yield: 76%) in an aqueous solution of pH 7. It has been reported that some microbes, such as Acinetobacter sp., Aerobacter sp., Acetobacter sp. and Escherichia sp., produce D-glucosaminic acid from D-glucosamine. As to enzymatic oxidation, D-glucosaminic acid was prepared by air oxidation of D-glucosamine catalyzed by glucose oxidase. However, glucose oxidase accepts D-glucosamine only as a poor substrate; the maximal catalytic efficiency was 2%. Thus, a better yield of D-glucosaminic acid was dependent on larger amounts of enzyme conjugated to longer reaction times (72 h).

Biosynthesis methods include many more procedures, such as culturing of strains, screening of strains, sterilization, etc. Currently, strict temperature controls, more by-products, longer reaction times, and lower purity of products limit the development of these methods. Therefore, the development of these methods requires many technological problems to be solved.

5.2.3. Electrocatalytical oxidation

Electrocatalytical oxidation of D-glucosamine was first reported by Yao et al.. The authors discussed the oxidation of glucose and derivatives at platinum black electrodes in pH 7.4 saline solution (isotonic with human plasma) with the objective of determining the feasibility of consuming such materials in an implantable energy conversion device. The anodic process would be oxidation of carbohydrates at an electrode with an associated diffusion membrane to prevent contact with blood or intercellular fluid, and the cathodic process would be reduction of oxygen. The catalytical effects of different electrode materials on the anodic oxidation process were further researched by Appleby and Drunen. The results obtained indicate that platinum, rhodium and Pt-Ru alloy electrodes are effective for glucose and D-glucosamine oxidations. In 2007, Tominaga et al. fulfilled the synthesis of D-glucosaminic acid using the novel approach of the electrocatalytic oxidation of D-glucosamine using gold electrodes and gold nanoparticle-modified carbon electrodes. The cyclic voltammetric results obtained indicated that D-glucosamine was catalytically oxidized in alkaline and neutral solutions. The controlled-potential electrolysis of D-glucosamine was possible in both alkaline and neutral solutions, and D-glucosaminic acid was identified as the 2-electron oxidation product. In particular, in an alkaline solution at a potential of-0.2 V, D-glucosaminic acid was formed as the 2-oxidation products with a current efficiency of 100%. When compared to the conventional synthesis method of D-glucosaminic acid, this synthesis approach is a useful alternative.

Although the electrocatalytical oxidation method overcomes the disadvantages of biosynthesis methods, such as more by-products and complicated processes, it is seldom adopted in industrial produce due to the higher energy consumption and the difficulty to control conditions.

In a word, although much research has been done on the synthesis of D-glucosaminic acid by metallic catalytical oxidation, electrocatalytical oxidation and biosynthesis methods, industrialized synthesis of D-glucosaminic acid has not yet been realized. The biosynthesis method produces higher yields, but some technological problems must be solved regarding the complicated procedures, such as separation of products, culture and screening of strains, etc. The noble-metal catalyzed oxidations with carbohydrates and derivatives have received increasing attention in recent years. In a number of cases, the selectivity of these catalytic processes can match those of enzymatic processes with the additional advantages of higher site-time yields and cleaner technologies. Thus, this method has received more and more attention. It is a promising synthesis method for D-glucosaminic acid in industry. However, there are still some parameters to be clarified in order to fulfill the necessary requirements for industrial development, such as an appropriate preparation system for catalysts and improvement of activity, stability and selectivity of catalysts.

References 144

  1. 1.

    Ravi Kumar MNV Muzzarelli RAA Muzzarelli C Sashiwa H Domb AJ Chitosan Chemistry and Pharmaceutical PerspectivesChem. Rev2004 10460176084

    Not in our library10.1021/cr030441b

  2. 2.

    Shahidi F Arachchi JKV Jeon YJ Food application of chitin and chitosanTrends Food Sci. Technol1999 103751

    Not in our library

  3. 3.

    Dodane V Vilivalam VD Pharmaceutical applications of chitosanPharm. Sci. Technol. Today1998 1246253

    Not in our library

  4. 4.

    Jeon YJ Shahidi F Kim SK Preparation of chitin and chitosan oligomers and thir application in physiological functional foodsFood Rev. Int2000 16159176

    Not in our library

  5. 5.

    Xia WS Physiological activities of chitosan and its application in functional foodsJ. Chin. Inst. Food Sci. Technol2003 317781

    Not in our library

  6. 6.

    Rinaudo M Chitin and chitosan: Properties and applicationsProg. Polym. Sci2006 31603632

    Not in our library

  7. 7.

    Kurita K Chemistry and application of chitin and chitosanPolym. Degrad. Stab1998 591–3117120

    Not in our library

  8. 8.

    Park JK Shimono K Ochiai N Shigeru K Kurita M Ohta Y Tanaka K Matsuda H Kawamukai M Purification, characterization, and gene analysis of a chitosanase (ChoA) from Matsuebacter Chitosanotabidus 3001J. Bacteriol1999 18166426649

    Not in our library10.1128/jb.181.21.6642-6649.1999

  9. 9.

    Abdel-Aziz SM Mostafa YA Moafi FE Partial Purification and Some Properties of the Chitosanases Produced by Bacillus Alvei Nrc-14J. Appl. Sci. Res2008 41012851290

    Not in our library

  10. 10.

    Chen X Xia WS Yu X Purification and characterization of two types of chitosanase from Aspergillus sp. CJ22–326Food Res. Int2005 38315322

    Not in our library

  11. 11.

    Zhang XY Zhang XK Kuroiwa K Kodaira R Shimosaka M Okazaki M Dai AL Purification and characterization of chitosanase and exo-β-D glucosaminidase from a Koji Mold, Aspergillus oryzae IAM2660Biosci. Biotech. Biochem2000 6418961902

    Not in our library10.1271/bbb.64.1896

  12. 12.

    Ouakfaoui SE Asselin A Diversity of chitosanase activity in cucumberPlant Sci1992 853341

    Not in our library

  13. 13.

    Park YM Ghim SY Enhancement of the activity and pH-performance of chitosanase from Bacillus cereus strains by DNA shufflingBiotechnol. Lett2009 3114631467

    Not in our library10.1007/s10529-009-0017-2

  14. 14.

    Charles-Rodriguez AV Mauricio-Benavides JE Garza-Garcia Y Aguilar CN Rodriguez-Herrera R Rodriguez J Contreras-Esquivel JC Chitosanase Production by a New Bacterial SourcesRes. J. Biol. Sci2008 2957963

    Not in our library

  15. 15.

    Yun C Amakata D Matsuo Y Matsuda H Kawamukai M New chitosan-degrading strains that produce chitosanases similar to ChoA of Mitsuaria chitosanitabidaAppl. Environ. Microbiol2005 7151385144

    Not in our library10.1128/aem.71.9.5138-5144.2005

  16. 16.

    Johnsen MG Hansen OC Stougaard P Isolation, characterization and heterologous expression of a novel chitosanase from Janthinobacterium sp. strain 4239Microb. Cell Fact2010 95

    Not in our library10.1186/1475-2859-9-5

  17. 17.

    Zhou W Yuan H Wang J Yao J Production, purification and characterization of chitosanase produced by Gongronella sp. JGLett. Appl. Microbiol2008 464954

    Not in our library10.1111/j.1472-765x.2007.02262.x

  18. 18.

    Xie Y Wei Y Hu J Depolymerization of chitosan with a crude cellulase preparation from Aspergillus nigerAppl. Biochem. Biotechnol2010 16010741083

    Not in our library10.1007/s12010-009-8559-2

  19. 19.

    Roncal T Oviedo A López de Armentia I Fernández L Villarán MC High yield production of monomer-free chitosan oligosaccharides by pepsin catalyzed hydrolysis of a high deacetylation degree chitosanCarbohydr. Res2007 34227502756

    Not in our library10.1016/j.carres.2007.08.023

  20. 20.

    Tanabe T Morinaga K Fukamizo T Mitsutomi M Novel chitosanase from Streptomyces griseus HUT 6037 with transglycosylation activityBiosci. Biotechnol. Biochem2003 67354364

    Not in our library10.1271/bbb.67.354

  21. 21.

    Kumar VAB Gowda LR Tharanathan RN A comparative study on depolymerization of chitosan by proteolytic enzymesCarbohydr. Polym2004 58275283

    Not in our library

  22. 22.

    Pantaleone D Yalpani M Scollar M Unusual susceptibility of chitosan to enzymatic hydrolysisCarbohydr. Res1992 237325332

    Not in our library

  23. 23.

    Muzzarelli RAA Xia WS Tomasetti M Ilari P Depolymerization of chitosan and substituted chitosans with the aid of a wheat germ lipase preparationEnzyme Microbial. Technol1995 17541545

    Not in our library

  24. 24.

    Lin SB Lin YC Chen HH Low molecular weight chitosan prepared with the aid of cellulase, lysozyme and chitinase: Characterisation and antibacterial activityFood Chem2009 11614753

    Not in our library

  25. 25.

    Qin CQ Du YM Enzymic preparation of water-soluble chitosan and their antitumor activityInt. J. Biol. Macromol2002 31111117

    Not in our library10.1016/s0141-8130(02)00064-8

  26. 26.

    Qin CQ Zhou B Zeng LT Zhang ZH Liu Y Du YM Xiao L The physicochemical properties and antitumor activity of cellulase-treated chitosanFood Chem2004 84107115

    Not in our library

  27. 27.

    Liu YJ Jiang Y Feng YF Han DL Study on the chitosan hydrolysis catalyzed by special cellulase and preparation of chitooligosaccharideJ. Func. Polym2005 18325329

    Not in our library

  28. 28.

    Liu J Xia WS Purification and characterization of a bifunctional enzyme with Chitosanase and cellulase activity from commercial cellulaseBiochem. Eng. J2006 308287

    Not in our library

  29. 29.

    Liu J Xia WS Characterization of chitosanase from cellulase produced by Trichoderma virideChin. J. Biochem. Mol. Biol2005 21713716

    Not in our library

  30. 30.

    Liu JN Xia WS Zhang JL Effects of Chitosans Physico–chemical Properties on Binding Capacities of Lipid and Bile Salts in vitroChin. Food Sci2008 2914549

    Not in our library

  31. 31.

    Xia WS Liu P Liu J Advance in chitosan hydrolysis by nonspecific cellulasesBioresour. Technol2008 991567516762

    Not in our library10.1016/j.biortech.2008.01.011

  32. 32.

    Xia WS Liu P Columbus F Characterization and mechanism of chitosan hydrolysis by nonspecific enzymesHandbook of Carbohydrate Polymers: Development, Properties and ApplicationsNova Science PublishersHauppauge, NY, USA2010 Chapter 2

    Not in our library

  33. 33.

    Shin SS Lee YC Lee C The degradation of chitosan with the aid of lipase from Rhizopus japonicus for the production of soluble chitosanJ. Food Biochem2001 25307321

    Not in our library

  34. 34.

    Xia WS Lee DX Purification and characterization of exo-β-D-glucosaminidase from commercial lipaseCarbohydr. Polym2008 743544551

    Not in our library

  35. 35.

    Lee DX Xia WS Zhang JL Enzymatic preparation of chitooligosaccharides by commercial lipaseFood Chem2008 111291295

    Not in our library10.1016/j.foodchem.2008.03.054

  36. 36.

    Muzzarelli RAA Tomasetti M Ilari P Deploymerization of chitosan with the aid of papainEnzyme Microbial. Technol1994 162110114

    Not in our library

  37. 37.

    Terbojevich M Cosani A Muzzarelli RAA Molecular parameters of chitosans depolymerized with the aid of papainCarbohydr. Polym1996 2916368

    Not in our library

  38. 38.

    Su C Xia WS Yao HY The relationship between structure of chitosan and papain activityJ. Wuxi Univ. Light Ind2002 21112115

    Not in our library

  39. 39.

    Sugano M Fujikawa T Hiratsuji Y Nakashima K Fukuda N Hasegawa Y A novel use of chitosan as a hypocholesterolemic agent in ratsAm. J. Clin. Nutr1980 33787793

    Not in our library10.1093/ajcn/33.4.787

  40. 40.

    Maezaki Y Tsuji K Nakagawa Y Kawai Y Akimoto M Tsugita T Hypochloesterolemic effect of chitosan in adult malesBiosci. Biotech. Biochem1993 5714391444

    Not in our library

  41. 41.

    Fukada Y Kimura K Ayaki Y Effect of chitosan feeding on intestinal bile acid metabolism in ratsLipids1991 26395939

    Not in our library10.1007/bf02537206

  42. 42.

    Ikeda I Sugano M Yoshida K Sasaki E Iwamoto Y Hatano K Effects of chitosan hydrolysates on lipid absorption and on serum and liver lipid concentration in ratsJ. Agric. Food Chem1993 41431435

    Not in our library

  43. 43.

    Cho YI No HK Meyers SP Physicochemical characteristics and functional properties of various commercial chitin and chitosan productsJ. Agric. Food Chem1998 4638393843

    Not in our library

  44. 44.

    Zhou K Xia WS Zhang C Yu L In vitro binding of bile acids and triglycerides by selected chitosan preparations and their physicochemical propertiesLWT–Food Sci. Technol2006 3910871092

    Not in our library

  45. 45.

    Razdan A Pettersson D Effect of chitin and chitosan on nutrient digestibility and plasma lipid concentrations in broiler chickensBr. J. Nutr1994 72277288

    Not in our library10.1079/bjn19940029

  46. 46.

    Liu JN Zhang JL Xia WS Hypocholesterolemic effects of different chitosan samples in vitro and in vivoFood Chem2008 107419425

    Not in our library

  47. 47.

    Deuchi K Kanauchi O Shizukuish M Kobayashi E Continuous and massive intake of chitosan effects mineral and fat–soluble vitamin status in rats fed on a high–fat dietBiosci. Biotech. Biochem1995 5912111216

    Not in our library10.1271/bbb.59.1211

  48. 48.

    Li L Zhang JL Liu JN Xia WS Effects of chitosan on serum lipid and fat liverChin. J. Mar. Drugs2007 26279

    Not in our library

  49. 49.

    Ahmad A Sumathi S Hameed B Residual oil and suspended solid removal using natural adsorbents chitosan, bentonite and activated carbon: a comparative studyChem. Eng. J2005 1081179185

    Not in our library

  50. 50.

    Deuchi K Kanauchi O Shizukuish M Kobayashi E Continuous and massive intake of chitosan effects mineral and fat–soluble vitamin status in rats fed on a high–fat dietBiosci. Biotech. Biochem1995 5912111216

    Not in our library10.1271/bbb.59.1211

  51. 51.

    Kittur FS Kumar ABV Gowda LR Tharanathan RN Chitosanolysis by a pectinase isozyme of Aspergillus niger—A non-specific activityCarbohydr. Polym2003 53191196

    Not in our library

  52. 52.

    Jung WJ Kuk JH Kim KY Jung KC Park RD Purification and characterization of exo-β-D-glucosaminidase from Aspergillus fumigatus S-26Protein Expression Purif2006 45125131

    Not in our library10.1016/j.pep.2005.06.016

  53. 53.

    Kittur FS Kumar ABV Varadaraj MC Tharanathan RN Chitooligosaccharides -preparation with the aid of pectinase isozyme from Aspergillus niger and their antibacterial activityCarbohydr. Res2005 34012391245

    Not in our library10.1016/j.carres.2005.02.005

  54. 54.

    Kittur FS Kumar ABV Varadaraj MC Tharanathan RN Low molecular weight chitosans—preparation by depolymerization with Aspergillus niger pectinase, and characterizationCarbohydr. Res2003 33812831290

    Not in our library10.1016/s0008-6215(03)00175-7

  55. 55.

    Li SL Wang C Xia WS Expression, purification and characterization of exo-β-D-glucosaminidase of Aspergillus sp. CJ22–326 from Escherichia coliCarbohydr. Res2009 34410461049

    Not in our library10.1016/j.carres.2009.02.026

  56. 56.

    Li SL Chen L Wang C Xia WS Expression, purification and characterization of endo–type chitosanase of Aspergillus sp. CJ22–326 from Escherichia coliCarbohydr. Res2008 3431730013004

    Not in our library10.1016/j.carres.2008.08.032

  57. 57.

    Shimosaka M Kumehara M Zhang XY Nogawa M Okazaki M Cloning and characterization of a chitosanase gene from the plant pathogenic fungus Fusarium solaniJ. Ferment. Bioeng1996 825426431

    Not in our library

  58. 58.

    Shimosaka M Sato K Nishiwaki N Miyazawa T Okazaki M Analysis of essential carboxylic amino acid residues for catalytic activity of fungal chitosanases by site-directed mutagenesisJ. Biosci. Bioeng2005 1005545550

    Not in our library10.1263/jbb.100.545

  59. 59.

    Wei XL Wang YF Xiao JB Xia WS Separation of chitooligosaccharides and the potent effects on gene expression of cell surface receptor CR3Int. J. Biol. Macromol2009 45432436

    Not in our library10.1016/j.ijbiomac.2009.07.003

  60. 60.

    Jeon YJ Shahidi F Kim SK Preparation of chitin and chitosan oligomers and their applications in physiological functional foodsFood Rev. Int2000 16159176

    Not in our library

  61. 61.

    Jeon YJ Kim SK Potential immuno–stimulating effect of antitumoral fraction of chitosan oligosaccharidesJ. Chitin Chitosan2001 6163167

    Not in our library

  62. 62.

    Wu GJ Tsai GJ Cellulase degradation of shrimp chitosan for the preparation of a water–soluble hydrolysate with immunoactivityFish. Sci2004 7011131120

    Not in our library

  63. 63.

    Feng J Zhao LH Yu QQ Receptor–mediated stimulatory effect of oligochitosan in macrophagesBiochem. Biophys. Res. Commun2004 317414420

    Not in our library10.1016/j.bbrc.2004.03.048

  64. 64.

    Le Cabec V Cols C Maridonneau–Parini I Nonopsonic Phagocytosis of Zymosan and Mycobacterium kansasii by CR3 (CD11b/CD18) Involves Distinct Molecular Determinants and is or is Not Coupled with NADPH Oxidase ActivationInfect. Immunol2000 6847364745

    Not in our library10.1128/iai.68.8.4736-4745.2000

  65. 65.

    Wei XL Wang YF Zhu Q Xiao JB Xia WS Effects of chitosan pentamer and chitosan hexamer in vivo and in vitro on gene expression and secretion of cytokinesFood Agric. Immunol2009 203269280

    Not in our library

  66. 66.

    Tokoro A Suzuki K Matsumoto T Mikami T Suzuki S Suzuki M Chemotactic response of human neutrophils to N–cetyl chitohexaose in vitroMicrobiol. Immunol1988 32387

    Not in our library10.1111/j.1348-0421.1988.tb01398.x

  67. 67.

    Tsukada K Matsumoto T Aizawa K Tokoro A Naruse R Suzuki S Suzuki M Antimetastatic and growth-inhibitory effects of N-acetylchitohexaose in mice bearing Lewis lung carcinomaJpn. J. Cancer Res1990 81259265

    Not in our library10.1111/j.1349-7006.1990.tb02559.x

  68. 68.

    Tokoro A Kobayashi M Tatewaki N Suzuki K Okawa Y Mikami T Suzuki S Suzuki M Protective effect of N-acetyl-chito-hexaose on Listeria monocytogenes infection in miceMicrobiol. Immunol1989 33357367

    Not in our library10.1111/j.1348-0421.1989.tb01983.x

  69. 69.

    Wang FY He YS Study on antitumor effect of water-soluble chitosanJ. Chin. Biochem. Drug2001 222122

    Not in our library

  70. 70.

    Khor E Chitin: Fulfilling a Biomaterials PromiseElsevier ScienceLondon, UK2001

    Not in our library

  71. 71.

    Jayakumar R Nwe N Tokura S Tamura H Sulfated chitin and chitosan as novel biomaterialsInt. J. Biol. Macromol2007 40175181

    Not in our library10.1016/j.ijbiomac.2006.06.021

  72. 72.

    Prashanth KVH Tharanathan RN Chitin/chitosan: modifications and their unlimited application potential— an overviewTrends Food Sci. Technol2007 18117131

    Not in our library

  73. 73.

    Qian RQ Glanville RW Methods for purifying chitosanUS Patent68968092005

    Not in our library

  74. 74.

    Baldrick P The safety of chitosan as a pharmaceutical excipientRegul. Toxic. Pharm2010 56290299

    Not in our library10.1016/j.yrtph.2009.09.015

  75. 75.

    Baker S Wiesmann WP Methods of making a chitosan product having an ultra–low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti–inflammatory cellular response to such materialsPCT/US2007/0238502008

    Not in our library

  76. 76.

    Sannan T Tsuchida S Yoshinaga S Seki M Purified chitins and production process thereofUS Patent69894402003

    Not in our library

  77. 77.

    Peniston QP Johnson EL Process for demineralization of crustacea shellsUS Patent40667351978

    Not in our library

  78. 78.

    Percot A Viton C Domard A Characterization of shrimp shell deproteinizationBiomacromolecules2003 4513801385

    Not in our library10.1021/bm034115h

  79. 79.

    No HK Meyers JSP Lee KS Isolation and Characterization of Chitin from Crawfish Shell WasteJ. Agric. Food Chem1989 373575579

    Not in our library

  80. 80.

    Hung WM Bergbauer KL Su KC Wang G Wages S Water–soluble chitosan having low endotoxin concentration and methods for making and using the sameUS Patent71259672006

    Not in our library

  81. 81.

    Cooper JF Prince R Bacterial Endotoxins TestMicrobiology in Pharmaceutical ManufacturingPDAShort Hills, NJ, USA2007 Chapter 22

    Not in our library

  82. 82.

    Shafaei A Ashtiani FZ Kaghazchi T Equilibrium studies of the sorption of Hg(II) ions onto chitosanChem. Eng. J2007 133311316

    Not in our library

  83. 83.

    Nguyen S Hisiger S Jolicoeur M Fractionation and characterization of chitosan by analytical SEC and 1H NMR after semi–preparative SECCarbohydr. Polym2009 75636645

    Not in our library

  84. 84.

    Lin CW Lin JC Characterization and blood coagulation evaluation of the water–soluble chitooligosaccharides prepared by a facile fractionation methodBiomacromolecules2003 4616911697

    Not in our library10.1021/bm034129n

  85. 85.

    Abdou ES Nagy KSA Elsabee MZ Extraction and characterization of chitin and chitosan from local sourcesBioresour. Technol2008 9913591367

    Not in our library10.1016/j.biortech.2007.01.051

  86. 86.

    Nguyen S Winnik FM Buschmann MD Improved reproducibility in the determination of the molecular weight of chitosan by analytical size exclusion chromatographyCarbohydr. Polym2009 75528533

    Not in our library

  87. 87.

    Trombotto S Ladaviere C Delolme F Chemical Preparation and Structural Characterization of a Homogeneous Series of Chitin/Chitosan OligomersBiomacromolecules2008 917311738

    Not in our library10.1021/bm800157x

  88. 88.

    Van De Velde K Kiekens P Structure analysis and degree of substitution of chitin, chitosan and dibutyrylchitin by FT–IR spectroscopy and solid state 13C NMRCarbohydr. Polym2004 58409416

    Not in our library

  89. 89.

    Muzzarelli RAA ChitinPergamon PressOxford, UK1977

    Not in our library

  90. 90.

    Okamoto Y Yano R Miyatake K Tomohiro I Shigemasa Y Minami S Effects of chitin and chitosan on blood coagulationCarbohydr. Polym2003 53337342

    Not in our library

  91. 91.

    Ishihara M Nakanishi K Ono K Sato M Kikuchi M Saito Y Yura H Matsui T Hattori H Uenoyama M Kurita A Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing processBiomaterials2002 23833840

    Not in our library10.1016/s0142-9612(01)00189-2

  92. 92.

    Wang X Yan Y Zhang R A comparison of chitosan and collagen sponges as hemostatic dressingsJ. Bioact. Compat. Polym2006 213954

    Not in our library

  93. 93.

    Gu R Sun W Zhou H Wu Z Meng Z Zhu X Tang Q Dong J Dou G The performance of a fly–larva shell–derived chitosan sponge as an absorbable surgical hemostatic agentBiomaterials2010 31612701277

    Not in our library10.1016/j.biomaterials.2009.10.023

  94. 94.

    Owens M Senrud A Teach J Gregory K A device for the deployment of internal esophageal chitosan bandageGastrointestinal Endoscopy GIE2006 635AB237

    Not in our library

  95. 95.

    Janvikul W Uppanan P Thavornyutikarn B Krewraing J Prateepasen R In vitro comparative hemostatic studies of chitin, chitosan, and their derivativesJ. Appl. Polym. Sci2006 102445451

    Not in our library

  96. 96.

    Bochicchio G Kilbourne M Kuehn R Keledjian K Hess J Scalea T Use of a modified chitosan dressing in a hypothermic Coagulopathic grade V liver injury modelAm. J. Surg2009 198617622

    Not in our library10.1016/j.amjsurg.2009.07.028

  97. 97.

    Ishihara M Ono K Saito Y Yura H Hattori H Matsui T Kurita A Photocrosslinkable chitosan: an effective adhesive with surgical applicationsInt. Cong. Ser2001 1223251257

    Not in our library

  98. 98.

    Hayashi T Matsuyama T Hanada K Nakanishi K Uenoyama M Fujita M Ishihara M Kikuchi M Ikeda T Tajiri H Usefulness of photocrosslinkable chitosan for endoscopic cancer treatment in alimentary tractJ. Biomed. Mater. Res. Part B Appl. Biomater2004 71B367372

    Not in our library10.1002/jbm.b.30099

  99. 99.

    Ono K Ishihara M Ozeki Y Deguchi H Sato M Saito Y Yura H Sato M Kikuchi M Kurita A Maehara T Experimental evaluation of photocrosslinkable chitosan as a biologic adhesive with surgical applicationsSurgery2001 130844850

    Not in our library10.1067/msy.2001.117197

  100. 100.

    Peng HT Shek PN Development of in situ–forming hydrogels for hemorrhage controlJ. Mater. Sci. Mater. Med2009 2017531762

    Not in our library10.1007/s10856-009-3721-5

  101. 101.

    Ong SY Wu J Moochhala SM Tan MH Lu J Development of a chitosan–based wound dressing with improved hemostatic and antimicrobial propertiesBiomaterials2008 2943234332

    Not in our library10.1016/j.biomaterials.2008.07.034

  102. 102.

    Hoemann CD Hurtig M Rossomacha E Sun J Chevrier A Shive MS Buschmann MD Chitosan-glycerol phosphate/blood implants improve hyaline cartilage repair in ovine microfracture defectsJ. Bone Joint. Surg. Am2005 871226712686

    Not in our library10.2106/jbjs.d.02536

  103. 103.

    Hoemann CD Sun J McKee MD Chevrier A Rossomacha E Rivard GE Hurtig M Buschmann MD Chitosan-glycerol phosphate/blood implants elicit hyaline cartilage repair integrated with porous subchondral bone in microdrilled rabbit defectsOsteoarthr. Cartilage2007 1517889

    Not in our library10.1016/j.joca.2006.06.015

  104. 104.

    Iliescu M Hoemann CD Shive MS Chenite A Buschmann MD Ultrastructure of Hybrid Chitosan-Glycerol Phosphate Blood Clots by Environmental Scanning Electron MicroscopyMicrosc. Res. Tech2008 71236247

    Not in our library10.1002/jemt.20545

  105. 105.

    Buschmann MD Hoemann CD Hurtig M Shive MS Williams RJ Cartilage Repair with Chitosan/Glycerol-Phosphate Stabilised Blood ClotsCartilage Repair StrategiesHumana PressTotowa, NJ, USA2007 85104

    Not in our library

  106. 106.

    Ogino A Kral M Yamashita M Nagatsu M Effects of low–temperature surface–wave plasma treatment with various gases on surface modification of chitosanAppl. Surf. Sci2008 25523472352

    Not in our library

  107. 107.

    Muzzarelli RAA Chitins and chitosans for the repair of wounded skin, nerve, cartilage and boneCarbohydr. Polym2009 76167182

    Not in our library

  108. 108.

    Hirsch JA Reddy SA Capasso WC Linfante I Non-invasive hemostatic closure devices: “patches and pads”Tech. Vasc. Intervent. Radiol2003 629295

    Not in our library10.1053/tvir.2003.36446

  109. 109.

    Muzzarelli RAA Muzzarelli C Chitosan chemistry: relevance to the biomedical scienceAdv. Polym. Sci2005 186151209

    Not in our library

  110. 110.

    Baldrick P The safety of chitosan as a pharmaceutical excipientRegul. Toxicol. Pharmacol2010 563290299

    Not in our library10.1016/j.yrtph.2009.09.015

  111. 111.

    Yang J Tian F Wang Z Wang Q Zeng YJ Chen SQ Effect of chitosan molecular weight and deacetylation degree on hemostasisJ. Biomed. Mater. Res. Part B Appl. Biomater2008 84B131137

    Not in our library10.1002/jbm.b.30853

  112. 112.

    Benesch J Tengvall P Blood protein adsorption onto chitosanBiomaterials2002 2325612568

    Not in our library10.1016/s0142-9612(01)00391-x

  113. 113.

    Wu Y Hu Y Cai J Ma S Wang X Coagulation property of hyaluronic acid–collagen/chitosan complex filmJ. Mater. Sci. Mater. Med2008 1936213629

    Not in our library10.1007/s10856-008-3477-3

  114. 114.

    Buschmann MD Hoemann CD Hurting MB Shive MS Williams RJ III Cartilage repair with chitosan–glycerol phosphate–stabilized blood clotsCartilage Repair StrategiesHumana PressTotowa, NJ, USA2007 85104

    Not in our library

  115. 115.

    Chou TC Fu E Wu CJ Yeh JH Chitosan enhances platelet adhesion and aggregationBiochem. Biophys. Res. Commun2003 302480483

    Not in our library10.1016/s0006-291x(03)00173-6

  116. 116.

    Klokkevold PR Fukayama H Sung EC Bertolami CN The effect of chitosan (poly–N–acetyl glucosamine) on lingual hemostasis in heparinized rabbitsJ. Oral. Maxillofac. Surg1999 574952

    Not in our library10.1016/s0278-2391(99)90632-8

  117. 117.

    Kim SW Rajapakse N Enzymatic production and biological activities of chitosan oligosaccharides (COS): a reviewCarbohydr. Polym2005 62357368

    Not in our library

  118. 118.

    Smith CJ Vournakis JN Demcheva M Fischer TH Differential effect of materials for surface hemostasis on red blood cell morphologyMicrosc. Res. Tech2008 71721729

    Not in our library10.1002/jemt.20612

  119. 119.

    Marchand C Rivard GE Sun J Hoemann CD Solidification mechanisms of chitosan–glycerol phosphate/blood implant for articular cartilage repairOsteoarthr Cartilage2009 177953960

    Not in our library10.1016/j.joca.2008.12.002

  120. 120.

    Wipff G Weiner P Kollman P A molecular–mechanics study of 18–crown–6 and its alkali complexes: an analysis of structural flexibility, ligand specificity, and the macrocyclic effectJ. Am. Chem. Soc1982 1041232493258

    Not in our library

  121. 121.

    Varela O Nin AP De Lederkremer R M.A short synthesis of (2S,4S,5R)-4,5,6-trihydroxynorleucineTetrahedron Lett1994 355093599362

    Not in our library

  122. 122.

    Gerspacher M Rapoport H 2–Amino–2–deoxyhexoses as chiral educts for hydroxylated indolizidines. Synthesis of (+)-castanospermine and (+)-6-epicastanospermineJ. Org. Chem1991 561137003706

    Not in our library

  123. 123.

    Bhat UR Forsberg LS Carlson RW Structure of lipid A component of Rhizobium leguminosarum bv phaseoli lipopolysaccharide. Unique nonphosph–orylated lipid A containing 2–amino–2–deoxygluconate galacturonate, and glucosamineJ. Biol. Chem1994 269201440214410

    Not in our library

  124. 124.

    Kanekiyo Y Aizawa S Koshino N Funahashi S Complexation equilibria of oxy-acid-2-amino-2-deoxy-D-gluconic acid–metal(II) ion ternary systems in aqueous solution as studied by potentiometry. Binding characteristics of borate and germanateInorg. Chim. Acta2000 2982154164

    Not in our library

  125. 125.

    Yu CJ Zhao JJ Guo YG Lu CL Ma X Gu ZW A novel method to prepare water-dispersible magnetic nanoparticles and their biomedical applications: Magnetic capture probe and specific cellular uptakeJ. Biomed. Mater. Res. Part A2008 87A2364372

    Not in our library10.1002/jbm.a.31786

  126. 126.

    Junicke H Arendt Y Steinborn D Synthesis and characterization of novel platinum (IV) complexes with functionalized carbohydratesInorg. Chim. Acta2000 3042224229

    Not in our library10.1016/s0162-0134(00)00088-x

  127. 127.

    Ou SJ Chen G Lin ZH Bai ZP Duan CY Mao CP Chromium(III) Complexes of D-Glucosaminic Acid and their Effect on Decreasing Blood Sugar in vivoArch. Pharmazie2006 3399527530

    Not in our library10.1002/ardp.200600053

  128. 128.

    Gu WX Xia WS Catalytic Synthesis of D-Glucosaminic Acid from D-Glucosamine on Active Charcoal–Supported Pd–Bi CatalystsJ. Carbohydr. Chem2006 254297301

    Not in our library

  129. 129.

    Pringsheim H Ruschman G Preparation of glucosaminic acidBerichte der Deutschen Chemischen Gesellschaft1915 48680682

    Not in our library

  130. 130.

    Wolfrom ML Dacons JC The Polymer–homologous Series of Oligosaccharides from CelluloseJ. Am. Chem. Soc1952 7453315333

    Not in our library

  131. 131.

    De Wilt HGJ Oxidation of glucose to gluconic acidInd. Eng. Chem. Prod. Res. Dev1972 114370373

    Not in our library

  132. 132.

    Smits PCC Kuster BFM Van Der Wiele K Van Der Baan HS The Selective Oxidation of Aldoses and Aldonic Acids to 2-Ketoaldonic Acids with Leadmodified Platinum-on-Carbon CatalystsCarbohydr. Res1986 153227235

    Not in our library

  133. 133.

    Heinen AW Peters JA Bekkum HV The oxidation of fructose on Pt/C catalysts. The formation of D-Threo-hexo-2,5-diulose and the effect of additivesCarbohydr. Res1997 3042155164

    Not in our library

  134. 134.

    Jenzer G Schneider MS Wandeler R Mallat T Baiker A Palladium-Catalyzed Oxidation of Octyl Alcohols in “Supercritical” Carbon DioxideJ. Catal2001 1991141148

    Not in our library

  135. 135.

    Pezzotti F Therisod H Therisod M Enzymatic synthesis of D-glucosaminic acid from D-glucosamineCarbohydr. Res2005 340139141

    Not in our library10.1016/j.carres.2004.10.013

  136. 136.

    Takiguchi Y Shiina A Yamaguchi T Bioconversion of D-glucosamine to D-glucosaminic acidNippon Nogeikagaku Kaishi2003 776576578

    Not in our library

  137. 137.

    Mitsubishi Gas Chemical Co., IGlucosaminic acid production by AeromonasJP Patent590111881984

    Not in our library

  138. 138.

    Mitsubishi Gas Chemical Co., ID-glucosaminic acid production by a new Aerononas strainJP Patent590147851984

    Not in our library

  139. 139.

    Mitsubishi Gas Chemical Co., IProducton of D-glucosaminic acid by Aerononas xanthus 102–1JP Patent590147861984

    Not in our library

  140. 140.

    Mitsubishi Gas Chemical Co., IProduction of D-glucosaminic acid by Aeromonas speciesJP Patent590147871984

    Not in our library

  141. 141.

    Mitsubishi Gas Chemical Co., IGlucosaminic acid production by AeromonasJP Patent821207741982

    Not in our library

  142. 142.

    Yao SJ Appleby AJ Geisel A Cash HR Wolfson SK Anodic Oxidation of Carbohydrates and their Derivatives in Neutral Saline SolutionNature1969 2245222921922

    Not in our library10.1038/224921a0

  143. 143.

    Appleby AJ Drunen CJV The oxygen evolution reaction on rhodium and iridium electrodes in 85% orthophosphoric acidJ. Electroanal. Chem1975 601101108

    Not in our library

  144. 144.

    Tominaga M Nagashima M Taniguchi I Controlled–potential electro- synthesis of glucosaminic acid from glucosamine at a gold electrodeElectrochem. Commun2007 95911914

    Not in our library

Cited by papers we hold 8

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.